© 2017 Pharmstandard Ventures
AquinoxPharmaceuticals
(NASDAQ:AQXP)
Vancouver, Canada
Year of Investment: 2013
Year of Exit: 2015-2016
IPO in March, 2014
Aquinox
Pharmaceuticals
(NASDAQ:AQXP)
Vancouver, Canada
Year of Investment: 2013
Year of Exit: 2015-2016
IPO in March, 2014
Aquinox is a clinical-stage pharmaceutical company developing targeted small molecule therapeutics for the treatment of cancer and inflammatory disease.Its lead product, AQX-1125, is aselective allosteric activator of SHIP1, a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. AQX-1125 is suitable for oral, once daily dosing; it has successfully completed multiple preclinical studies and seven clinical trials, and is now advancing into Phase 3 trials in lead indication of bladder interstitial cystitis / bladder pain syndrome (IC/BPS).

For more information, please visit:
www.aqxpharma.com

Pharmstandard Ventures is looking for innovative drug discovery/development projects targeting the unmet medical needs or providing dramatic advantages over the competition globally